Should I Buy SVRA? SVRA 2026 Analysis

Should You Buy Savara Inc (SVRA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

5.580

1 Day change

-0.53%

52 Week Range

7.000

Analysis Updated At

2026/01/26

Savara Inc (SVRA) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has positive momentum with bullish moving averages, insider buying trends, and strong analyst support with increasing price targets. Despite some legal concerns, the company's progress on its Molbreevi drug launch and improved financial metrics make it a solid long-term investment opportunity.

Technical Analysis

The technical indicators show bullish momentum. The MACD is positive and contracting, RSI is neutral at 49.316, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot level of 6, with resistance at 6.368 and support at 5.631.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The low put-call ratios suggest a bullish sentiment in the options market.

Technical Summary

Sell

Buy

Positive Catalysts

Insider buying has increased significantly by 373.33% over the last month.
Analysts have raised price targets, with a consensus of $9-$10, citing a $1B opportunity for Molbreevi in aPAP.
The company has resolved manufacturing deficiencies and is on track for regulatory submissions.
Positive stock trend predictions with a 13.51% chance of increase in the next month.

Neutral/Negative Catalysts

Legal investigation related to fiduciary duties following shareholder losses due to FDA rejection of Molbreevi BLA.
Financials show no revenue and a net loss of $29.56M in Q3 2025, though improving year-over-year.

Financial Performance

In Q3 2025, the company showed improvement in net income (-$29.56M, up 21.91% YoY) and EPS (-0.14, up 27.27% YoY). However, revenue and gross margin remain at 0.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are bullish on SVRA. H.C. Wainwright raised the price target to $10 from $8, Oppenheimer raised it to $9 from $8, and Citizens JMP adjusted it to $10 from $11. All maintain Buy or Outperform ratings, citing strong execution and a significant market opportunity for Molbreevi.

6 Analyst Rating

Wall Street analysts forecast SVRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SVRA is 10.17 USD with a low forecast of 9 USD and a high forecast of 11 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 5.610

Low

Averages

10.17

High

Current: 5.610

Low

Averages

10.17

High

H.C. Wainwright

Andrew Fein

Buy

maintain

$8 -> $10

AI Analysis

2025-12-23

Reason

H.C. Wainwright

Andrew Fein

Price Target

$8 -> $10

AI Analysis

2025-12-23

maintain

Buy

Reason

H.C. Wainwright analyst Andrew Fein raised the firm's price target on Savara to $10 from $8 and keeps a Buy rating on the shares. The company resubmitted the application for Molbreevi with Fujifilm Diosynth as its drug substance manufacturer, the analyst tells investors in a research note. The firm believes Savara is increasingly well positioned ahead of a potential Molbreevi launch.

Oppenheimer

Outperform

maintain

$8 -> $9

2025-11-14

Reason

Oppenheimer

Price Target

$8 -> $9

2025-11-14

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on Savara to $9 from $8 and keeps an Outperform rating on the shares. Ahead of December 2025 BLA submission for MOLBREEVI, the firm continues to see a more than $1B opportunity for MOLBREEVI in aPAP following recent updated claims data giving line of sight to at least 1,000 patients by launch with 750 already identified.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SVRA

Unlock Now

SVRA Should I Buy

SVRA Should I Buy

Should You Buy Savara Inc (SVRA) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch